NCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
Clinical Trials
268 trialsNCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT06138496 2026-01-05
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Completed
NCT04704219 2025-12-03
KEYNOTE-B61
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03075423 2025-09-26
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Goethe University
Phase 2 Completed
NCT05263245 2025-09-03
Skippy 1
Leiden University Medical Center
Phase 2 Completed
NCT03685448 2025-08-08
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03967522 2025-08-08
CABRAMET
Centre Leon Berard
Phase 2 Completed
NCT03297593 2025-06-06
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Swiss Cancer Institute
Phase 2 Completed
NCT02440334 2025-05-04
Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
Thomas Jefferson University
Phase 2 Completed
NCT03173560 2025-04-01
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
Eisai Inc.
Phase 2 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT01767636 2025-03-03
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
Phase 2 Completed
NCT01130519 2025-02-21
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01884961 2025-01-13
IL2HD
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT02761057 2025-01-13
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Phase 2 Completed
NCT04068831 2024-12-27
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01693822 2024-11-21
A-PREDICT
Institute of Cancer Research, United Kingdom
Phase 2 Completed
NCT02639182 2024-11-18
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Phase 2 Completed
NCT02819596 2024-11-04
CALYPSO
Queen Mary University of London
Phase 2 Completed
NCT03109015 2024-10-08
ASSET
Duke University
Phase 2 Completed
NCT03108066 2024-09-24
MK-3795-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT05485896 2024-09-19
Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Completed
NCT00554515 2024-08-28
SELECT
Beth Israel Deaconess Medical Center
Phase 2 Completed
NCT00378482 2024-08-22
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Phase 2 Completed
NCT03097328 2024-04-29
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03890731 2024-04-02
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Phase 2 Completed
NCT03126331 2024-03-18
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00019396 2024-03-04
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019539 2024-03-04
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03012581 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT03511391 2024-01-23
CHEERS
University Hospital, Ghent
Phase 2 Completed
NCT04134390 2024-01-09
CABOMAYOR
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT03680521 2023-10-04
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
Mirati Therapeutics Inc.
Phase 2 Completed
NCT01517243 2023-09-21
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT00075660 2023-08-04
3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01689766 2023-07-25
Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
Endocyte
Phase 2 Completed
NCT03679767 2023-07-21
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Incyte Corporation
Phase 2 Completed
NCT00068393 2023-07-07
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02579811 2023-06-29
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00003308 2023-06-22
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00039429 2023-06-22
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01689662 2023-06-22
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma
Endocyte
Phase 2 Completed
NCT00077129 2023-06-18
Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01164228 2023-06-15
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04535687 2023-06-13
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT02853344 2023-04-11
MK-3475-427
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03428217 2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2 Completed